

Director: Ashley Frazer-Abel, PhD, D(ABMLI)

Exsera BioLabs

1775 Aurora Court, Room 3209

Aurora, CO 80045

ExseraBioLabs@UCDenver.edu

Phone: 303-724-7592

Non-Clinical & Clinical Trials

Why Exsera BioLabs?

While we may be a new Lab, we are not new to the field. Our Director has written more than 100 Principal Investigator/Contributing Scientist reports and has overseen many more studies. Combine that with a team with decades of experience in complement testing. Exsera BioLabs is exceptionally capable of offering insight and experience that can be applied to your work and understanding your unique issues or results.



Commitment to Understand the Immunological Effects of Large Molecules:

While it was oligonucleotide based therapeutics that brought us into the IND field, we have experience with antibody based test articles as well as antibodydrug conjugates and other biologics; therefore, we have seen many pro-inflammatory and often anaphylactoid outcomes of direct test article activation of complement as well as activation secondary to anti-drug or drug component antibodies.

Commitment to Quality:

Our second team member brought on board was a QA Specialist with more than 20 years experience in the field, demonstrating the importance we put on quality and compliance. In addition, because we are building this laboratory from the ground up, we have been able to start with a strong foundation in current industry expectations, regulations and guidance.





Commitment to Timely Results:

We understand that you cannot wait for your data, so we have prioritized meeting expectations for data delivery timelines that are facilitated by a robust sample tracking system.

Commitment to Building an Experienced Team:

Our director, Dr. Frazer-Abel, has more than a decade of experience in clinical and non-clinical complement and immunoinflammatory testing and our laboratory team members have an average of more than 15 years of experience in the field.

| Validated & Orderable | |
|----------------------------|-----------------------|
| Human | NHP |
| CH50 | CH50 |
| AH50 | AH50 |
| Bb | Bb |
| C3a | C3a |
| sC5b-9 | sC5b-9 |
| C3 | C3 |
| C4 | C4 |
| Factor B | Factor B |
| C5a | |
| Validation Planned Q2 2017 | |
| Human | NHP |
| Intact C3 | C5 Function |
| iC3b/C3b | C3 Function |
| C1q | C2 Function |
| Properdin | C4 Function |
| Circulating Immune | Circulating Immune |
| Complexes | Complexes |
| Wieslab CP | Properdin |
| Wieslab AP | Validation Q3 2017 |
| Wieslab MP | Wieslab CP |
| C5, C3, C4, C2 Function | Wieslab AP |
| Factor H Level | Wieslab MP |
| MBL | C4a |
| Multiplex Comp. | Ва |
| Validation Q3 2017 | Cytokines |
| Ва | Assays in Development |
| C2 | C5a |
| C4b | Factor I |
| C5 | C5 |
| Factor D | Expected Q3 2017 |
| Factor I | Canine |
| C4a | CH50 |
| Cytokines | C3, C5 Function |
| Assays in Development | Assays in Development |
| Complement Genetics | Rodent |
| Factor I Function | C3a |
| | Factor H |

Commitment to Compliance:

We have built our laboratory and assays to be in compliance with CAP, CLIA88, FDA GLPs, FDA GCP, ICH E6.